A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
The purpose of this observational study is to assess the effectiveness and safety of Nivolumab plus Ipilimumab with or without chemotherapy as first-line treatment for participants with untreated advanced or recurrent NSCLC in the real world setting in Japan.
Non-Small Cell Lung Cancer
Duration of treatment, Time from the initiation date of nivolumab plus ipilimumab with or without chemotherapy among eligible participants to the last date of treatment as an event., Up to 1 year|Rates of participants with second-line treatment, The rate of eligible participants who have completed nivolumab plus ipilimumab with or without chemotherapy during the observation period and have initiated second-line treatment, Up to 1 year|Overall survival (OS), Defined as the time between the date of initiation of nivolumab plus ipilimumab with or without chemotherapy and the date of death from any cause among eligible participants., Up to 1 year|Incidence of Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 Grade 3 or higher immune-related adverse events [irAEs], Up to 1 year|Time to next treatment [(TNT), Defined as the time between the date of combination therapy with nivolumab plus ipilimumab with or without chemotherapy initiation among eligible participants and the date of second-line treatment initiation or the date of death from any cause, whichever occurs first., Up to 1 year|Treatment-free survival (TFS), Defined as the time between the date of nivolumab plus ipilimumab with or without chemotherapy cessation among eligible participants and the date of second-line treatment initiation or the date of death from any cause, whichever occurs first., Up to 1 year|Treatment continuation rate, The rate of eligible participants who have continued nivolumab plus ipilimumab with or without chemotherapy during the observation period., Up to 1 year|Incidence of treatment-related adverse events (TRAEs) leading to treatment discontinuation, Up to 1 year
Progression-free survival (PFS) in participants assessed for tumor response according to RECIST v 1.1, Up to 1 year|Objective response rate (ORR) in participants evaluated for tumor response according to RECIST v 1.1, Up to 1 year|Disease control rate (DCR) in participants evaluated for response in accordance with RECIST v 1.1, Up to 1 year|Duration of response (DOR) in participants evaluated for tumor response in accordance with RECIST v 1.1, Up to 1 year|Overall Survival (OS) by patient background, Up to 1 year|Time to next treatment (TNT) by patient background, Up to 1 year|Treatment-free survival (TFS) by patient background, Up to 1 year|Treatment continuation rate by patient background, Up to 1 year|Incidence of CTCAE v 5.0 Grade 3 or higher irAEs by patient background, Up to 1 year|Incidence of TRAEs leading to treatment discontinuation by patient background, Up to 1 year|Overall survival of nivolumab plus ipilimumab with or without chemotherapy by adjustment for confounding factors, Up to 1 year|Time to next treatment of nivolumab plus ipilimumab with or without chemotherapy by adjustment for confounding factors, Up to 1 year|Treatment-free survival of nivolumab plus ipilimumab with or without chemotherapy by adjustment for confounding factors, Up to 1 year|Treatment continuation rate of nivolumab plus ipilimumab with or without chemotherapy by adjustment for confounding factors, Up to 1 year|Incidence of CTCAE v 5.0 Grade 3 or higher irAEs of nivolumab plus ipilimumab with or without chemotherapy by adjustment for confounding factors, Up to 1 year|Incidence of TRAEs leading to treatment discontinuation of nivolumab plus ipilimumab with or without chemotherapy by adjustment for confounding factors, Up to 1 year|Time to onset of immune-related adverse events (irAEs) to be collected, treatment for these events and time to symptom improvement, and impact on effectiveness, Up to 1 year|Duration of treatment of second-line treatment, Up to 1 year|Reasons for treatment discontinuation of second-line treatment, Up to 1 year|Treatment related death of second-line treatment, Up to 1 year|Response rate of second-line treatment, Up to 1 year|Overall survival in participants who discontinued treatment due to treatment-related adverse events within 90 days, Up to 1 year|Time to next treatment in participants who discontinued treatment due to treatment-related adverse events within 90 days, Up to 1 year|Treatment-free survival in participants who discontinued treatment due to treatment-related adverse events within 90 days, Up to 1 year|Treatment continuation rate in participants who discontinued treatment due to treatment-related adverse events within 90 days, Up to 1 year|Duration of treatment of second-line treatment in participants with disease progression within 90 days, Up to 1 year|Reasons for treatment discontinuation of second-line treatment in participants with disease progression within 90 days, Up to 1 year|Overall survival of second-line treatment in participants with disease progression within 90 days, Up to 1 year|Response rate of second-line treatment in participants with disease progression within 90 days, Up to 1 year|Treatment related death of second-line treatment in participants with disease progression within 90 days, Up to 1 year
The purpose of this observational study is to assess the effectiveness and safety of Nivolumab plus Ipilimumab with or without chemotherapy as first-line treatment for participants with untreated advanced or recurrent NSCLC in the real world setting in Japan.